COMMUNIQUÉS West-GlobeNewswire
-
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
21/05/2026 -
SpyGlass Pharma to Participate in Upcoming Investor Conferences
21/05/2026 -
NSK Dental Achieves Back-to-Back Top Ratings in Dental Product Shopper Peer Evaluations
21/05/2026 -
CytomX Therapeutics to Present at Upcoming June Investor Conferences
21/05/2026 -
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
21/05/2026 -
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
21/05/2026 -
Nanobiotix annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
21/05/2026 -
Brain Cancer Canada Awards The Dwayne Andrews Glioblastoma Research Grant to Tackle One of the Most Aggressive Brain Tumours and Unlock Immunotherapy Breakthroughs for Young Patients
21/05/2026 -
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
21/05/2026 -
Medicana Strengthens Its International Sports Presence Through Expanded Healthcare Partnership with Fenerbahçe
21/05/2026 -
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
21/05/2026 -
HNL Lab Medicine Receives 2026 Boomi Innovation Award for Advancing Integration and Automation in Healthcare
21/05/2026 -
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
21/05/2026 -
‘For The Assist’: Haleon Canada launches national campaign with Canada Soccer to celebrate the small health supports behind Canadian wellbeing
21/05/2026 -
Genvor Appoints Donald Kalkofen as Chief Financial Officer
21/05/2026 -
Iovance Biotherapeutics to Present at Upcoming Conference
21/05/2026 -
Tvardi Therapeutics to Participate in Upcoming Investor Events
21/05/2026 -
New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®
21/05/2026 -
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
21/05/2026
Pages